当前位置: 首页 > 期刊 > 《中国当代医药》 > 2009年第9期
编号:12056182
乳酸/羟基乙酸共聚物分子量对艾塞那肽微球性质的影响(2)
http://www.100md.com 2009年3月25日 《中国当代医药》 2009年第9期
     [参考文献]

    [1]谭兴容.Exendin-4与糖尿病治疗[J].重庆医学, 2006, 35(10):904.

    [2]Yu BS, Wang AR.Glucagon-like peptide 1 based therapy for type 2 diabetes[J].World J Pediatr,2008, 4(1):8-13.

    [3]Ai G, Chen Z, Shan C.Single-and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys[J]. Int J Pharm,2008, 353(1-2):56-64.

    [4]Drucker DJ, Buse JB, Taylor K, et al. Trautmann, D. Zhuang, L. Porter, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study[J]. Lancet. 2008, 372(9645):1240-1250.

    [5]孙华燕, 徐风华.溶剂挥发法制备蛋白质类微球的研究进展[J].中国新药杂志,2008, 17(3):195-198.

    [6]Van der Walle CF, Sharma G, Ravi Kumar M. Current approaches to stabilising and analysing proteins during microencapsulation in PLGA[J]. Expert Opin Drug Deliv,2009, 6(2):177-86.

    [7]Xu Q,Czernuszka JT.Controlled release of amoxicillin from hydroxyapatite-coated poly(lactic-co-glycolic acid) microspheres[J].J Control Release,2008, 127(2):146-153.

    [8]王襄平, 梅兴国.乳酸/羟基乙酸共聚物分子量及其单体组成比例对利培酮微球性质的影响[J].中国药房,2007, 18(1):38-41.

    (收稿日期:2009-03-05), http://www.100md.com
上一页1 2